Literature DB >> 31069400

Single-centre retrospective review of risk factors for local tumour progression and complications in radiofrequency ablation of 555 hepatic lesions.

Jasmine Ming Er Chua1, Yu Ming Paul Lam2, Bien Soo Tan1, Kiang Hiong Tay1, Apoorva Gogna1, Farah Gillan Irani1, Hoau Gong Richard Lo1, Chow Wei Too1.   

Abstract

INTRODUCTION: This study aimed to assess safety, local tumour progression (LTP) and risk factors for LTP after radiofrequency ablation (RFA) of liver tumours in a single centre.
METHODS: All consecutive patients treated with RFA for liver tumours between January 2009 and October 2012 were included. Previously treated lesions that progressed were excluded. Using electronic medical records, the following data was captured: patient demographics, pre-procedural laboratory results, Child-Pugh status, tumour characteristics, development of tumoral seeding, RFA complications and LTP. Possible risk factors for LTP were identified using Cox regression.
RESULTS: In total, 555 liver tumours were treated in 337 patients. 483 (87.0%) hepatocellular carcinomas, 52 (9.4%) colorectal metastases and 20 (3.6%) other tumour types were treated. Mean tumour size was 2.1 ± 1.1 (range 0.4-6.8) cm. Mean follow-up duration was 387 days. 416 (75.0%) lesions had no LTP at the last imaging. 70 (12.6%) patients had minor complications requiring observation, while 7 (1.3%) patients had significant complications requiring prolonged hospitalisation or further interventions. Only one case of tumour seeding was detected. Using multivariate Cox regression, the following factors were statistically significant in predicting LTP: hilar location (relative ratio [RR] 3.988), colorectal metastases (RR 2.075), size (RR 1.290) and younger age (RR 0.982).
CONCLUSION: RFA of liver tumours is safe and effective, with a low significant complication rate of 1.3%. Hilar lesions are most prone to LTP, followed by lesions that were larger in size and colorectal metastases. 75.0% of patients showed no LTP at the last follow-up. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  complication; liver tumours; local tumour progression; radiofrequency ablation

Mesh:

Year:  2019        PMID: 31069400      PMCID: PMC6482426          DOI: 10.11622/smedj.2019036

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  30 in total

1.  Quality improvement guidelines for the reporting and archiving of interventional radiology procedures.

Authors:  Reed A Omary; Michael A Bettmann; John F Cardella; Curtis W Bakal; Mark S Schwartzberg; David Sacks; Kenneth S Rholl; Steven G Meranze; Curtis A Lewis
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

2.  Adverse events during radiofrequency treatment of 582 hepatic tumors.

Authors:  Thierry de Baère; Olivier Risse; Viseth Kuoch; Clarisse Dromain; Christophe Sengel; Tarek Smayra; Mostafa Gamal El Din; Christian Letoublon; Dominique Elias
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

3.  Characterization of the RF ablation-induced 'oven effect': the importance of background tissue thermal conductivity on tissue heating.

Authors:  Zhengjun Liu; Muneeb Ahmed; Yehuda Weinstein; Ming Yi; Roop L Mahajan; S Nahum Goldberg
Journal:  Int J Hyperthermia       Date:  2006-06       Impact factor: 3.914

4.  Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations.

Authors:  Takuma Teratani; Haruhiko Yoshida; Shuichiro Shiina; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Norio Mine; Yuji Kondo; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

5.  Radiofrequency ablation for hepatocellular carcinoma and metastatic liver tumors: a comparative study.

Authors:  Danny H F Chow; Lorraine H Y Sinn; Kelvin K Ng; Chi Ming Lam; Jimmy Yuen; Sheung Tat Fan; Ronnie T P Poon
Journal:  J Surg Oncol       Date:  2006-12-01       Impact factor: 3.454

6.  Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  1999-03       Impact factor: 11.105

7.  Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy.

Authors:  Hsien-Chung Yu; Jin-Shiung Cheng; Kwok-Hung Lai; Chi-Pin Lin; Gin-Ho Lo; Chiun-Ku Lin; Ping-I Hsu; Hoi-Hung Chan; Ching-Chu Lo; Wei-Lun Tsai; Wen-Chi Chen
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 8.  Tumor ablation with radio-frequency energy.

Authors:  G S Gazelle; S N Goldberg; L Solbiati; T Livraghi
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

9.  Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned.

Authors:  Richard J Bleicher; David P Allegra; Dean T Nora; Thomas F Wood; Leland J Foshag; Anton J Bilchik
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

10.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

View more
  3 in total

1.  Optical signatures of radiofrequency ablation in biological tissues.

Authors:  Pranav Lanka; Kalloor Joseph Francis; Hindrik Kruit; Andrea Farina; Rinaldo Cubeddu; Sanathana Konugolu Venkata Sekar; Srirang Manohar; Antonio Pifferi
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

2.  miR-210 is a Serological Biomarker for Predicting Recurrence and Prognosis of Colon Carcinoma Patients with Liver Metastases After Radiofrequency Ablation Treatment.

Authors:  Yong Zhang; Yu-Mei Zhou; Zu-Jian Zhang; Xin Li
Journal:  Cancer Manag Res       Date:  2020-09-25       Impact factor: 3.989

3.  The Learning Curve for Thermal Ablation of Liver Cancers: 4,363-Session Experience for a Single Central in 18 Years.

Authors:  Xiang Jing; Yan Zhou; Jianmin Ding; Yijun Wang; Zhengyi Qin; Yandong Wang; Hongyu Zhou
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.